经鼻高流量氧疗与常规氧疗治疗COVID-19相关急性呼吸衰竭:系统评价与Meta分析
该系统评价与Meta分析检索MEDLINE、Embase、Web of Science和CENTRAL数据库,纳入至2022年12月发表的比较经鼻高流量氧疗(HFNC)与常规氧疗(COT)治疗COVID-19相关急性呼吸衰竭的随机对照试验(RCT)和观察性研究。共分析20项研究、8383例患者,包括6项RCT(2509例)和14项观察性研究(5874例)。合并6项RCT显示,HFNC较COT显著降低插管风险(RR 0.89,95%CI 0.80~0.98;p=0.02),并缩短住院时间;但未显著降低死亡风险(RR 0.93,95%CI 0.77~1.11;p=0.40)。提示HFNC可减少插管需求、缩短住院时间,但死亡获益未达统计学显著。
要点
- 合并6项RCT(2509例)显示,HFNC较COT显著降低COVID-19相关急性呼吸衰竭患者的插管风险(RR 0.89,95%CI 0.80~0.98;p=0.02)。
- HFNC未显著降低死亡风险(RR 0.93,95%CI 0.77~1.11;p=0.40)。
- 共纳入20项研究、8383例患者:6项RCT(2509例)与14项观察性研究(5874例),观察性研究仅用于敏感性分析。
- 主要结局为RCT中的插管风险与死亡风险,效应量为风险比(RR)及95%CI。
适用人群与场景
- COVID-19相关急性呼吸衰竭患者。
- 排除儿科研究、将HFNC与非COT的其他无创呼吸支持比较的研究、未报告插管或死亡的研究。
研究设计与关键结果
- 研究类型:系统评价与Meta分析,检索MEDLINE、Embase、Web of Science和CENTRAL数据库,纳入英文发表的RCT和观察性研究,检索时间自建库至2022年12月。
- 共纳入20项研究、8383例患者,包括6项RCT(2509例)和14项观察性研究(5874例);观察性研究用于敏感性分析。
- 主要结局(合并6项RCT):HFNC较COT显著降低插管风险(RR 0.89,95%CI 0.80~0.98;p=0.02),并缩短住院时间。
- 主要结局(合并6项RCT):HFNC未显著降低死亡风险(RR 0.93,95%CI 0.77~1.11;p=0.40)。
- 根据统计异质性采用固定效应或随机效应模型进行Meta分析。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入RCT与观察性研究,主要结局基于6项RCT。
- 研究已在PROSPERO注册,注册号CRD42022340035(06/20/2022)。
- 局限:原文未报告局限性
对床旁实践的改变
- 对COVID-19相关急性呼吸衰竭患者,HFNC较COT可降低插管风险并缩短住院时间,但未显著降低死亡风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The effectiveness of high-flow nasal cannula oxygen therapy (HFNC) in patients with acute respiratory failure due to COVID-19 remains uncertain. We aimed at assessing whether HFNC is associated with reduced risk of intubation or mortality in patients with acute respiratory failure due to COVID-19 compared with conventional oxygen therapy (COT).
METHODS: In this systematic review and meta-analysis, we searched MEDLINE, Embase, Web of Science, and CENTRAL databases for randomized controlled trials (RCTs) and observational studies comparing HFNC vs. COT in patients with acute respiratory failure due to COVID-19, published in English from inception to December 2022. Pediatric studies, studies that compared HFNC with a noninvasive respiratory support other than COT and those in which intubation or mortality were not reported were excluded. Two authors independently screened and selected articles for inclusion, extracted data, and assessed the risk of bias. Fixed-effects or random-effects meta-analysis were performed according to statistical heterogeneity. Primary outcomes were risk of intubation and mortality across RCTs. Effect estimates were calculated as risk ratios and 95% confidence interval (RR; 95% CI). Observational studies were used for sensitivity analyses.
RESULTS: Twenty studies were analyzed, accounting for 8383 patients, including 6 RCTs (2509 patients) and 14 observational studies (5874 patients). By pooling the 6 RCTs, HFNC compared with COT significantly reduced the risk of intubation (RR 0.89, 95% CI 0.80 to 0.98; p = 0.02) and reduced length of stay in hospital. HFNC did not significantly reduce the risk of mortality (RR 0.93, 95% CI 0.77 to 1.11; p = 0.40).
CONCLUSIONS: In patients with acute respiratory failure due to COVID-19, HFNC reduced the need for intubation and shortened length of stay in hospital without significant decreased risk of mortality. Trial registration The study was registered on the International prospective register of systematic reviews (PROSPERO) at https://www.crd.york.ac.uk/prospero/ with the trial registration number CRD42022340035 (06/20/2022).
参考来源
- Le Pape S, Savart S, Arrivé F, et al. High-flow nasal cannula oxygen versus conventional oxygen therapy for acute respiratory failure due to COVID-19: a systematic review and meta-analysis. Ann Intensive Care. 2023. PMID: 37994981. doi:10.1186/s13613-023-01208-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。